Judgment of Novartis Glivec: Taj Pharma and Indian healthcare companies Gains in India

The Indian generics giant ‘Taj Pharma’ CEO A.K.Singh said in an interview with Bloomberg “the decision will have a positive impact on drug affordability, accessibility and availability of this drug in India for cancer (myeloid leukemia) patents, as Glivec (imatinib) costs more than Rs.10 lacks for monthly treatment compared to Rs.10,000 for our generic imatinib tablets”

Source: https://www.1888pressrelease.com/judgment-of-novartis-glivec-taj-pharma-and-indian-healthcar-pr-644895.html